

REMARKS

In the Office Communication dated June 26, 2009, the Examiner states that:

this application fails to comply with the requirements of 37 C.F.R. §§ 1.821-1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures. Applicant must comply with the requirements of the sequence rules (37 CFR 1.821 - 1.825) before the application can be examined under 35 U. S. C. §§ 131 and 132.

Office Communication at 1. Accordingly, Applicants contacted the USPTO for technical assistance to revise the Sequence Listing to comply with the sequence rules. The errors listed in the Validation Report have been addressed and Applicants submit the revised Sequence Listing herewith.

CONCLUSION

In view of the foregoing amendment and remarks, Applicants respectfully request reconsideration of this application and the timely allowance of the pending claims.

Please grant any extensions of time required to enter this response and charge any additional required fees to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

By: 

Mark D. Sweet
Reg. No. 41,469
(202) 408-4000

Dated: July 27, 2009